#BEGIN_DRUGCARD DB01582

# AHFS_Codes:
Not Available

# ATC_Codes:
J01EB03

# Absorption:
Rapidly absorbed following oral administration.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
57-68-1

# ChEBI_ID:
102265

# Chemical_Formula:
C12H14N4O2S

# Chemical_IUPAC_Name:
4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide

# Chemical_Structure:
Not Available

# Creation_Date:
2007-08-29 08:54:18 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Infective Agents
Sulfonamides

# Drug_Interactions:
Chlorpropamide	Sulfonamide/sulfonylurea: possible hypoglycemia
Cyclosporine	The sulfonamide decreases the effect of cyclosporine
Methotrexate	The sulfamide increases the toxicity of methotrexate

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.89

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1500 mg/L (at 29 °C)

# Food_Interactions:
Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.

# GenBank_ID:
Not Available

# Generic_Name:
Sulfamethazine

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)

# InChI_Key:
InChIKey=ASWVTGNCAZCNNR-UHFFFAOYSA-N

# Indication:
For the treatment bacterial infections causing bronchitis, prostatitis and urinary tract infections.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1582

# Mechanism_Of_Action:
Sulfonamides inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydropteroic acid by competing with PABA for binding to dihydrofolate synthetase, an intermediate of tetrahydrofolic acid (THF) synthesis. THF is required for the synthesis of purines and dTMP and inhibition of its synthesis inhibits bacterial growth. Pyrimethamine and trimethoprim inhibit dihydrofolate reductase, another step in THF synthesis, and therefore act synergistically with the sulfonamides.

# Melting_Point:
198.5 °C

# Molecular_Weight_Avg:
278.33

# Molecular_Weight_Mono:
278.083746402

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451542

# Pharmacology:
Sulfamethazine is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase). Sulfamethazine is bacteriostatic in nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and DNA.

# Predicted_LogP_Hydrophobicity:
0.43

# Predicted_LogS:
-3.1

# Predicted_Water_Solubility:
2.30e-01 g/l

# Primary_Accession_No:
DB01582

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5327

# PubChem_Substance_ID:
46507146

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Sulfamethazine may cause nausea, vomiting, diarrhea and hypersensitivity reactions. Hematologic effects such as anemia, agranulocytosis, thrombocytopenia and hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency may also occur. Sulfamethoxazole may displace bilirubin from albumin binding sites causing jaundice or kernicterus in newborns.

# Update_Date:
2013-02-08 16:20:18 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
7.59

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
nat

# Phase_1_Metabolizing_Enzyme_1_ID:
6938

# Phase_1_Metabolizing_Enzyme_1_Name:
Arylamine N-acetyltransferase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
Not Available

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P0A5L8

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
21084778	Friaza V, Morilla R, Respaldiza N, de la Horra C, Calderon EJ: Pneumocystis jiroveci dihydropteroate synthase gene mutations among colonized individuals and Pneumocystis pneumonia patients from Spain. Postgrad Med. 2010 Nov;122(6):24-8.
4577373	Thijssen HH: A simplified radioassay method of dihydropteroate synthetase activity in Escherichia coli and its application for an inhibition study of p-aminobenzoi acid derivatives. Anal Biochem. 1973 Jun;53(2):579-85.
7486915	Hong YL, Hossler PA, Calhoun DH, Meshnick SR: Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X68776

# Drug_Target_1_GenBank_ID_Protein:
41273

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
folP

# Drug_Target_1_Gene_Sequence:
>849 bp
ATGAAACTTTTTGCCCAGGGTACTTCACTGGACCTTAGCCATCCTCACGTAATGGGGATC
CTCAACGTCACGCCTGATTCCTTTTCGGATGGTGGCACGCATAACTCGCTGATAGATGCG
GTGAAACATGCGAATCTGATGATCAACGCTGGCGCGACGATCATTGACGTTGGTGGCGAG
TCCACGCGCCCAGGGGCGGCGGAAGTTAGCGTTGAAGAAGAGTTGCAACGTGTTATTCCT
GTGGTTGAGGCAATTGCTCAACGCTTCGAAGTCTGGATCTCAGTCGATACATCCAAACCA
GAAGTCATCCGTGAGTCAGCGAAAGTTGGCGCTCACATTATTAATGATATCCGCTCCCTT
TCCGAACCTGGCGCTCTGGAGGCGGCTGCAGAAACCGGTTTACCGGTTTGTCTGATGCAT
ATGCAGGGAAATCCAAAAACCATGCAGGAAGCTCCGAAGTATGACGATGTCTTTGCAGAA
GTGAATCGCTACTTTATTGAGCAAATAGCACGTTGCGAGCAGGCGGGTATCGCAAAAGAG
AAATTGTTGCTCGACCCCGGATTCGGTTTCGGTAAAAATCTCTCCCATAACTATTCATTA
CTGGCGCGCCTGGCTGAATTTCACCATTTCAACCTGCCGCTGTTGGTGGGTATGTCACGA
AAATCGATGATTGGGCAGCTGCTGAACGTGGGGCCGTCCGAGCGCCTGAGCGGTAGTCTG
GCCTGTGCGGTCATTGCCGCAATGCAAGGCGCGCACATCATTCGTGTTCATGACGTCAAA
GAAACCGTAGAAGCGATGCGGGTGGTGGAAGCCACTCTGTCTGCAAAGGAAAACAAACGC
TATGAGTAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
1522070	Dallas WS, Gowen JE, Ray PH, Cox MJ, Dev IK: Cloning, sequencing, and enhanced expression of the dihydropteroate synthase gene of Escherichia coli MC4100. J Bacteriol. 1992 Sep;174(18):5961-70.
1657875	Talarico TL, Dev IK, Dallas WS, Ferone R, Ray PH: Purification and partial characterization of 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase and 7,8-dihydropteroate synthase from Escherichia coli MC4100. J Bacteriol. 1991 Nov;173(21):7029-32.
8304179	Swedberg G, Fermer C, Skold O: Point mutations in the dihydropteroate synthase gene causing sulfonamide resistance. Adv Exp Med Biol. 1993;338:555-8.
9187658	Achari A, Somers DO, Champness JN, Bryant PK, Rosemond J, Stammers DK: Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nat Struct Biol. 1997 Jun;4(6):490-7.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
891

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
30616

# Drug_Target_1_Name:
Dihydropteroate synthase

# Drug_Target_1_Number_of_Residues:
282

# Drug_Target_1_PDB_ID:
1AJZ

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00809	Pterin_bind

# Drug_Target_1_Protein_Sequence:
>Dihydropteroate synthase
MKLFAQGTSLDLSHPHVMGILNVTPDSFSDGGTHNSLIDAVKHANLMINAGATIIDVGGE
STRPGAAEVSVEEELQRVIPVVEAIAQRFEVWISVDTSKPEVIRESAKVGAHIINDIRSL
SEPGALEAAAETGLPVCLMHMQGNPKTMQEAPKYDDVFAEVNRYFIEQIARCEQAGIAKE
KLLLDPGFGFGKNLSHNYSLLARLAEFHHFNLPLLVGMSRKSMIGQLLNVGPSERLSGSL
ACAVIAAMQGAHIIRVHDVKETVEAMRVVEATLSAKENKRYE

# Drug_Target_1_Reaction:
(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate + 4-aminobenzoate = diphosphate + 7,8-dihydropteroate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DHPS catalyzes the formation of the immediate precursor of folic acid. It is implicated in resistance to sulfonamide

# Drug_Target_1_SwissProt_ID:
P0AC13

# Drug_Target_1_SwissProt_Name:
DHPS_ECOLI

# Drug_Target_1_Synonyms:
DHPS
Dihydropteroate pyrophosphorylase
EC 2.5.1.15

# Drug_Target_1_Theoretical_pI:
5.95

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01582
